CoMFA analysis of dual/multiple PPAR activators.
暂无分享,去创建一个
[1] C. Cerletti,et al. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. , 2003, Trends in pharmacological sciences.
[2] L. Moore,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] V. Cody,et al. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. , 2000, Journal of medicinal chemistry.
[4] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[5] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[6] E. Knaus,et al. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers. , 2004, Journal of medicinal chemistry.
[7] T. Willson,et al. Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ , 2001 .
[8] J. Auwerx,et al. Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones , 1997, Current Pharmaceutical Design.
[9] T. Moon,et al. Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells. , 2004, Biological & pharmaceutical bulletin.
[10] T. Willson,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.
[11] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[12] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] Rakesh Kumar,et al. Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARα/γ dual agonists , 2007 .
[14] Igor I Baskin,et al. Selectivity fields: comparative molecular field analysis (CoMFA) of the glycine/NMDA and AMPA receptors. , 2003, Journal of medicinal chemistry.
[15] P. Bharatam,et al. Additivity of Molecular Fields: CoMFA Study on Dual Activators of PPARα and PPARγ , 2005 .
[16] A. Mittal,et al. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. , 2006, Mini reviews in medicinal chemistry.
[17] R. Castle. Topics in heterocyclic chemistry , 1969 .
[18] B. Henke. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. , 2004, Journal of medicinal chemistry.
[19] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[20] A. Gangjee,et al. Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents. , 2003, Journal of Medicinal Chemistry.
[21] R. S. Mulliken. Electronic Population Analysis on LCAO–MO Molecular Wave Functions. I , 1955 .
[22] C. Charlier,et al. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. , 2003, European journal of medicinal chemistry.
[23] J. Lehmann,et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.